• Research & Development

  Treprostinil Prevents Cellular Responses Linked to Arterial Remodeling and PAH, Study Reveals

  Posted by Pulmonary Hypertension News Moderator on November 19, 2018 at 1:11 pm

  Treprostinil is a therapy that works to reduce pulmonary artery narrowing in people with pulmonary arterial hypertension (PAH) by preventing artery wall remodeling processes. That finding comes from a research study investigating the medicine’s molecular effects using patient lung artery cells suggests.

  Treprostinil appears to work by stopping artery wall remodeling by inhibiting the release of growth factors, proliferation of cells, and deposits of collagen and fibronectin in the arteries’ walls. All these effects are signaled through another molecule called cyclic AMP (cAMP), whose levels are increased by treprostinil, the study shows. Learn more here.

  Are you interested in more information about this topic?

  replied 7 years, 3 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply